Search
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … [L15302] Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes,[L15292] as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.
Remifentanil
go.drugbank.com/drugs/DB00899ApprovedInvestigationalRemifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.
Products: REMIFENTANIL MYLAN GENERICSHaemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB10990ApprovedHaemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received
Pegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigational[A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is available as a fixed dose combination product with [DB11574] (tradename Zepatier) used for the treatment of chronic Hepatitis C. … Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Grazoprevir.
Nimodipine
go.drugbank.com/drugs/DB00393ApprovedInvestigationalNimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Products: NIMODIPINA DOC GENERICI, NIMODIPINA MYLAN GENERICSCX-052075
go.drugbank.com/drugs/DB31655Approved[L53408] As opposed to previously approved COVID-19 mRNA vaccines, including the original Moderna COVID-19 vaccine ([elasomeran]), CX-052075 encodes only the immunodominant regions (NTD and RBD) of … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigationalAsparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. … [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic
Metreleptin
go.drugbank.com/drugs/DB09046ApprovedInvestigational[A263126] Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized